44 results on '"Boni C"'
Search Results
2. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
3. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer
4. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
5. Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
6. Primary chemotherapy in operable breast carcinoma comparing CMF (cyclophosphamide, methotrexate, 5-fluorouracil) with an anthracycline-containing regimen: short-term responses translated into long-term outcomes
7. Non-small-cell lung cancer: which platinum for gemcitabine?
8. The new drugs advent: clinical or economic outcomes?
9. Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)
10. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas
11. PHASE II RANDOMIZED TRIAL COMPARING THREE PLATINUM-BASED DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER
12. TEMOZOLOMIDE AS SECOND LINE CHEMOTHERAPY IN THE TREATMENT OF RECURRENT MALIGNANT GLIOMAS
13. Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM)
14. Second-line chemotherapy in advanced pancreatic cancer patients before nab-paclitaxel introduction. Retrospective study in Reggio Emilia Clinical Cancer Centre
15. The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy
16. Relationship between HER-2 amplification and tumor infiltrating lymphocytes in breast cancer patients treated with neoadjuvant trastuzumab
17. EGFR-related miRNAs as potential biomarkers of response to Erlotinib in metastatic NSCLC patients
18. C-Met : a possible predictive role for response to treatment in metastatic renal cel carcinoma
19. The phase III study INTERCEPTOR in locally advanced head and neck cancer (LA-HNC). Preliminary safety report
20. Relationship between levels of HER-2 amplification and pathologic complete response to trastuzumab-based neoadjuvant treatment
21. Association with programmed death ligand-1 (PDL-1) expression and Helicobacter Pylori infection in patients with non-diffuse type gastric carcinoma
22. E17 - Updated report of an observational clinical registry (REGCLIN-MM) on malignant pleural mesothelioma (MPM)
23. Immunohistochemical Screening Using Egfr Mutation-Specific Antibodies in Lung Adenocarcinomas: Diamond Project
24. Folfoxiri Plus Bevacizumab (Bv) or Plus Anti-Egfr Antibodies in Ras and Braf Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts): Analysis of Tumor Response
25. Folfoxiri Plus Bevacizumab (Bev) As First-Line Treatment of Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts)
26. Three or Six Months of Adjuvant Chemotherapy for Colon Cancer: Compliance and Safety of the Phase III Italian Tosca Trial
27. Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study
28. F17 - The STAR score predicts prognosis in Luminal-like breast cancer patients independently from dose-dense adjuvant chemotherapy
29. F18 - Relationship between HER-2 amplification and tumor infiltrating lymphocytes in breast cancer patients treated with neoadjuvant trastuzumab
30. B20 - Second-line chemotherapy in advanced pancreatic cancer patients before nab-paclitaxel introduction. Retrospective study in Reggio Emilia Clinical Cancer Centre
31. Medical Optimization of Torisel® (MOTOR): A Phase II Trial of Temsirolimus as Second-Line Treatment for Advanced RCC by the Italian Kidney Cancer Group (GIR)
32. Pain Management in Eight Italian Oncological Care Centres
33. A Randomized Phase III Study Evaluating the Continuation of Bevacizumab (BV) Beyond Progression in Metastatic Colorectal Cancer (MCRC) Patients (PTS) Who Received BV as Part of First-Line Treatment: Results of the Bebyp Trial by the Gruppo Oncologico Nord Ovest (GONO)
34. 1318P - Immunohistochemical Screening Using Egfr Mutation-Specific Antibodies in Lung Adenocarcinomas: Diamond Project
35. 504PD - Three or Six Months of Adjuvant Chemotherapy for Colon Cancer: Compliance and Safety of the Phase III Italian Tosca Trial
36. 517P - Folfoxiri Plus Bevacizumab (Bev) As First-Line Treatment of Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts)
37. 515P - Folfoxiri Plus Bevacizumab (Bv) or Plus Anti-Egfr Antibodies in Ras and Braf Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients (Pts): Analysis of Tumor Response
38. O-0007 - Subgroup Analyses in RAS Mutant, BRAF Mutant and “ALL WT” Metastatic Colorectal Cancer Patients Treated with Folfoxiri Plus Bevacizumab (BEV) or Folfiri Plus BEV in the Tribe Study
39. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study
40. Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?
41. Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)
42. Original article: Fluorouracil-alone versus high-dose folinic acid and fluorouracil in advanced colorectal cancer: A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC)
43. Cisplatin and etoposide in advanced colorectal carcinoma
44. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.